Personal tools
You are here: Home In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit
Navigation
Subscribe or renew subscription
Google Ad Links
 
Document Actions

In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit

From The Cancer Letter, Dec. 18, 2009:

In a recommendation that will likely have broad implications for FDA approval of “maintenance” therapies for advanced cancer, the FDA Oncologic Drugs Advisory Committee voted 12-1 against approval of Tarceva (erlotinib) as maintenance in the treatment of non-small cell lung cancer.

For the rest of the story, which examines why Alimta got its NDA in this indication while Tarceva is likely headed for defeat, click on The Cancer Letter Archive at left to read the Dec. 18 issue (subscription or day pass required).

Also in this issue:
  • President Obama signs bill giving 2.8 percent increase to NCI.
_____
tags:
Friday, December 18, 2009 in FDAdrug development  | Permalink |  Comments (0)
del.icio.us   Digg   Yahoo   Google   Spurl
Log in


Forgot your password?
Top Headlines
« March 2010 »
Su Mo Tu We Th Fr Sa
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31
2010-03-05 00:00
00:00-00:00 Obama's Virtual Colonoscopy Sets Off Real-World Turf War Of Specialty Groups
00:00-00:00 ACS Prostate Cancer Screening Guideline Urges Doctor-Patient Informed Decision
2010-03-12 00:00
00:00-00:00 NCI Advisors Approve Recompetition Of $132 Million Proteomic Network
12:00-12:00 NCI Puts Genentech Studies On Hold, Citing IP Disagreement
Categories:
FDA (15)
Medicare (3)
NCI (33)
cancer prevention (4)
cancer screening (18)
cancer treatment (14)
drug development (30)
legislation (4)
news makers (3)
oncology profession (2)
policy issues (30)
research funding (38)
Google Ads
 

Powered by Plone CMS, the Open Source Content Management System

This site conforms to the following standards: